Welcome to our dedicated page for Chemours Co SEC filings (Ticker: CC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Chemours Co's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Chemours Co's regulatory disclosures and financial reporting.
Chemours Co (CC) entered into a Settlement Agreement with the State of North Carolina and 11 local entities to resolve claims relating to PFAS and other emissions from its Fayetteville Works facility, as well as certain PFAS contamination elsewhere in the state, including from aqueous film-forming foam. The agreement calls for aggregate payments of $455 million over 15 years, beginning within 30 days of execution, and remains subject to court orders dismissing the covered claims. Under existing cost-sharing arrangements, Chemours will bear 50% of the settlement payments, with DuPont and Corteva sharing the remaining 50%. Chemours states its approximately $180 million net present value share is covered by existing accruals, and expects about $50 million of payments in the next twelve months. The Settlement Amount will count as about $210 million of qualified spend under the parties’ $4 billion MOU cap, and combined with a 2025 New Jersey settlement eliminates the need for further contributions to the MOU escrow account, including Chemours’ $50 million contribution previously due in September 2026.
Chemours Co (CC) furnished an investor presentation outlining its strategy, segment performance and capital structure as of the second quarter of 2026. For Q2 2026, the company generated $1.59 billion in net sales and $247 million in Adjusted EBITDA, but recorded a net loss attributable to Chemours of $274 million. Adjusted EPS was $0.42, while free cash flow reached $114 million, a 128% year‑over‑year increase, with 46% free cash flow conversion.
The presentation details the “Pathway to Thrive” plan targeting more than $250 million of cost reductions from 2024–2027, 5%+ sales CAGR and long‑term net leverage below 3.0x. Trailing twelve‑month net sales were $5.80 billion with Adjusted EBITDA of $733 million, including Titanium Technologies net sales of $2.39 billion and Adjusted EBITDA of $725 million at a 34% margin.
Chemours highlights growth in low‑GWP Opteon refrigerants, data center and semiconductor applications, and a mid‑cycle Adjusted EBITDA floor target of $400 million for Titanium Technologies. The company reports gross debt of $3.9 billion, net debt of $3.2 billion, and Q2 2026 net leverage of 4.4x, supported by €230 million of recent term‑loan repayment and approximately $287 million initial net proceeds from the Kuan Yin site sale, while continuing to resolve legacy environmental and PFAS‑related matters through settlements and mitigation commitments.
Chemours Co Chief Accounting Officer David Will reported a Form 4 transaction involving 2,426 shares of common stock on August 12, 2026. These shares were automatically withheld to satisfy tax obligations upon vesting of restricted stock units and related dividend equivalent units, at a value of $15.24 per share. The filing specifies that no shares were sold in the open market. Following this tax-withholding disposition, Will’s holdings, including directly owned shares, restricted stock units, and dividend equivalent units, total 30,868.097 shares.
Chemours Co executive Gerardo Familiar Calderon, President of Advanced Performance Materials, purchased 1,935 shares of Common Stock on August 12, 2026 at $15.53 per share in an open-market or private transaction. Following this transaction, his directly owned and equity-based holdings total 58,547.3746 shares, which include directly owned shares, restricted stock units, and dividend equivalent units, and reflect an adjustment correcting an administrative error in prior reports.
Chemours Co Chief Executive Officer and director Denise Dignam purchased 3,378 shares of Chemours common stock on 2026-08-11 at $14.95 per share in an open-market transaction. Following this trade, she directly owns a total of 339,916.3423 shares, which includes directly owned shares, restricted stock units and dividend equivalent units, with the total adjusted to correct an administrative error in prior reports.
Chemours Co executive Michael Robert Foley, President of Titanium Technologies, purchased 1,934.2313 shares of common stock on August 7, 2026 in an open-market transaction at a weighted average price of $15.51 per share, with individual trade prices ranging from $15.51 to $15.54.
Chemours Co director Alister Cowan purchased 13,000 shares of Chemours common stock on August 7, 2026 in an open-market transaction at a weighted average price of $15.62 per share, with individual trade prices ranging from $15.58 to $15.62. Following this purchase, Cowan’s directly owned holdings, including restricted stock units and dividend equivalent units, total 56,988.0387 shares.
Chemours Co director Mary B. Cranston purchased 6,000 shares of Chemours common stock in an open-market transaction on 2026-08-07 at a price of $15.825 per share. Following this purchase, she reports beneficial ownership of 113,140.9469 shares, which includes directly owned shares, restricted stock units, and dividend equivalent units.
Chemours Co executive Joseph T. Martinko, President of Thermal & Specialized Solutions, reported a purchase of 1,939.8014 shares of common stock on August 7, 2026 at $15.47 per share in an open-market or private transaction. Following this transaction, his reported direct holdings total 55,431.4012 shares, which include directly owned shares, restricted stock units, and dividend equivalent units.
Chemours Co Chief Financial Officer Shane Hostetter purchased common stock in a personal transaction. On 2026-08-06, he bought 3,350 shares of Chemours common stock at $14.94 per share. Following this purchase, he directly and beneficially owned a total of 102,697.7058 shares, which includes directly owned shares, restricted stock units, and dividend equivalent units.